Logo image
Recombinant human coagulation factor VIIa in Jehovah's witness patients undergoing liver transplantation
Journal article   Open access   Peer reviewed

Recombinant human coagulation factor VIIa in Jehovah's witness patients undergoing liver transplantation

Nicolas Jabbour, Singh Gagandeep, Peilin Alice Cheng, Brendan Boland, Rod Mateo, Yuri Genyk, Rick Selby, Gary Zeger and Gagandeep P. Singh
American Surgeon, Vol.71(2)
2005

Abstract

Adult Aged alpha 1-Antitrypsin Deficiency Anemia Blood Transfusion, Autologous Blood Volume Cadaver Cause of Death Coagulants Factor VIIa Female Hemodilution Humans Jehovah's Witnesses Liver Cirrhosis Liver Transplantation Living Donors Male Middle Aged Recombinant Proteins Religion and Medicine recombinant blood clotting factor 7a blood clotting factor 7a coagulating agent recombinant protein adult aged anemia article blood clotting disorder blood volume cadaver donor clinical article disease severity female graft rejection hemodilution human Jehovah's witness liver failure liver transplantation living donor male organ donor postoperative complication preoperative care treatment outcome alpha 1 antitrypsin deficiency anemia blood autotransfusion cadaver cause of death Jehovah's witness liver cirrhosis methodology middle aged religion
Indisputably, liver transplantation is among the most technically challenging operations in current practice and is compounded by significant coagulopathy and portal hypertension. Recombinant human coagulation factor VIIa (rFVIIa) is a new product that was initially described to treat bleeding in hemophilia patients. We present in this paper 10 liver transplants in Jehovah's Witness patients using this novel product at University of Southern California-University Hospital. The subject population included nine males and one female with an average age of 50 years. Six patients underwent cadaveric and four live donor liver transplantation. Surgeries were conducted following our established protocol for transfusion-free liver transplantation, which includes preoperative blood augmentation, intraoperative blood salvage, acute normovolemic hemodilution, and postoperative blood conservation. Factor rFVIIa was used at a dose of 80 μg/kg intravenously just prior to the incision in all patients, and a second intraoperative dose was used in 3 patients. All living donor liver transplantation (LDLT) recipients did well and were discharged uneventfully with normal liver functions. Two of the six cadaveric recipients died. One patient died intraoperatively from acute primary graft nonfunction, and the other died 38 hours postoperatively from severe anemia. This report suggests factor rFVIIa might have a much broader application in surgery in the control of bleeding associated with coagulopathy.
url
https://doi.org/10.1177/000313480507100216View
Published (Version of record) Open

Metrics

10 Record Views

Details

Logo image